Hepcortespenlisimut-L is under clinical development by Immunitor and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData, Phase III drugs for Hepatocellular Carcinoma have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Hepcortespenlisimut-L’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hepcortespenlisimut-L overview

Hepcortespenlisimut-L (V5) is under development for the treatment of hepatocellular carcinoma. V5 is adjunct oral immunotherapy. It is a bivalent vaccine derived from the pooled blood of hepatitis B and C carriers. V5 inherently contains circulating M. tuberculosis antigens. V5 involves heat- and chemical inactivation with subsequent formulation into a tablet. It was also under development for the treatment of tuberculosis, HIV/AIDS and hepatitis C.

Immunitor overview

Immunitor, a subsidiary of Immune Network Ltd is a developer of orally-delivered immune therapies. The company’s proprietary technology formulates vaccines as oral pills. Its products are used prevent and treat viral infections such as HIV, hepatitis B and C, influenza, tuberculosis, broad spectrum bacterial and fungal infections, cancer, and atherosclerosis and obesity. Immunitor’s technology enables to formulate vaccines as oral pills. In addition, the company offers therapeutic vaccines and oral products. It operates GMP manufacturing facilities in Thailand. Immunitor is headquartered in Vancouver, British Columbia, Canada.

For a complete picture of Hepcortespenlisimut-L’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.